Risk of grand mal status epilepticus in primary malignant brain tumor patients treated with anti-neoplastic therapy.

Object. The purpose of this study was to examine patterns of diagnosis and relative survival rates in individuals in whom a primary malignant brain tumor was diagnosed between 1973 and 1997; follow-up review of these patients continued through the end of 1999. Methods. The study population was composed of 21,493 patients with primary malignant brain tumors that were diagnosed between 1973 and 1997. Data on these patients were obtained from the population-based Surveillance, Epidemiology, and End Results Program. The study population was divided into three cohorts based on the year of diagnosis, and these groups were compared with respect to variables of interest by performing chi-square tests and relative survival analysis with the life table method. Over time, there were consistently more men, more Caucasians, more patients undergoing surgery, and more individuals 70 years and older who received the diagnosis of primary malignant brain tumor. An examination of proportions of individuals with astrocytoma, other; oligodendroglioma, other; and oligodendroglioma Grade III showed significant temporal changes with frontal and temporal lobe tumors occurring most often. The diagnosis was obtained at an earlier age in African-American than in Caucasian patients. Caucasians had higher proportions of glioblastoma multiforme (GBM), which was associated with decreased survival times, and of oligodendroglioma, other, whereas African Americans had higher proportions of astrocytoma, other; ependymoma Grade II or III; and medulloblastoma, all of which were associated with increased survival times. The relative survival case demonstrated a continuous improvement over time, although older patients, those who underwent biopsy only, and those with GBMs continue to have the poorest survival times. The relative survival rates of African Americans consistently were similar or worse than those of Caucasians when the groups were stratified by prognostic factors. Conclusions. Over time, the relative survival rate of individuals with primary malignant brain tumor has improved and differences in survival are seen by examining the race of the patients.

Download Full-text

Phase I-II Trials of Poly(ICLC) in Malignant Brain Tumor Patients

Journal of Interferon Research ◽

10.1089/jir.1982.2.1 ◽

1982 ◽

Vol 2 (1) ◽

pp. 1-4 ◽

Cited By ~ 20

Author(s):

OSAMU NAKAMURA ◽

NOBUYUKI SHITARA ◽

MASAO MATSUTANI ◽

KINTOMO TAKAKURA ◽

HARUHIKO MACHIDA

Keyword(s):

Brain Tumor ◽

Phase I ◽

Malignant Brain Tumor ◽

Tumor Patients

Download Full-text

Primary malignant brain tumor incidence and Medicaid enrollment

Neurology ◽

10.1212/wnl.63.11.2197 ◽

2004 ◽

Vol 63 (11) ◽

pp. 2197-2197

Author(s):

H. Greenberg ◽

P. R. Sherwood

Keyword(s):

Brain Tumor ◽

Malignant Brain Tumor ◽

Tumor Incidence ◽

Medicaid Enrollment ◽

Primary Malignant Brain Tumor

Download Full-text

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?

Cancers ◽

10.3390/cancers12123775 ◽

2020 ◽

Vol 12 (12) ◽

pp. 3775

Author(s):

Giuseppe Lombardi ◽

Ahmed Idbaih ◽

Emilie Le Rhun ◽

Matthias Preusser ◽

Vittorina Zagonel ◽

...

Keyword(s):

Brain Tumor ◽

Recurrent Glioblastoma ◽

Malignant Brain Tumor ◽

Adult Patients ◽

Primary Malignant Brain Tumor

Glioblastoma is the most common and aggressive primary malignant brain tumor in adult patients [...]

Download Full-text

Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.11522 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 11522-11522 ◽

Cited By ~ 4

Author(s):

J. Kirkpatrick ◽

A. Desjardins ◽

J. J. Vredenburgh ◽

J. A. Quinn ◽

J. N. Rich ◽

...

Keyword(s):

Monoclonal Antibody ◽

Brain Tumor ◽

Glioblastoma Multiforme ◽

Malignant Gliomas ◽

Malignant Brain Tumor ◽

Phase Iii ◽

New Combination ◽

Dramatic Improvement ◽

Vegf Receptor ◽

Tumor Patients

11522 Background: The prognosis for glioblastoma multiforme remains poor. Survival is generally limited to less than 1 year. Currently available standard treatments have not allowed, thus far, to prolong survival significantly. Response rates observed in clinical trials evaluating glioblastoma multiforme are usually less than 20%. Knowing that malignant gliomas have high concentrations of VEGF receptors, and the higher the VEGF receptor concentration, the worse the prognosis, we decided to evaluate the efficacy of bevacizumab in malignant brain tumor patients. Bevacizumab is a humanized IgG1 monoclonal antibody to VEGF, which is synergistic with chemotherapy for most malignancies. We performed a phase II study combining bevacizumab with irinotecan for patient with malignant gliomas and observed an unprecedented response rate of 63%. Methods: Building of those results, we decided to treat a number of our patients with voluminous unresectable disease with bevacizumab and temozolomide as an upfront regimen. Temozolomide is an oral methylating agent known effective for primary malignant brain tumor patients. A phase III trial, first presented at the ASCO meeting of 2003, demonstrated the efficacy of temozolomide for newly diagnosed glioblastoma multiforme patients, establishing temozolomide as the new standard of care. Given the known results with temozolomide as monotherapy and the combination of bevacizumab with irinotecan, we treated patients with temozolomide and bevacizumab upfront. Results: With this new combination, some patients demonstrated dramatic improvement clinically and radiographically. The combination has been well tolerated thus far, with no incidence of hemorrhage or arterial thrombosis observed. Conclusions: Results will be updated at the time of presentation. [Table: see text]

Download Full-text